hotspot -WSS

hotspot

author：focus 2025-08-11 07:59:22 - browse：51189

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

WSS

Second House panel advances two

IRA could hurt research into orphan drugs for rare diseases

Private equity could exacerbate cardiology's overuse problem, experts fear

Pig kidney works a record two months in donated body

Second House panel advances two

WATCH: Why do bright lights make us see spots?

leisure time

hotspot

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Generate Biomedicines machine learning biotech raises $273M

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Telehealth for opioid use disorder is lifesaving

Dobbs anniversary: the lost opportunity of abortion as health care

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Walensky prepares to leave CDC — and Congress — behind

Telehealth for opioid use disorder is lifesaving

Trump demands the U.S. pay no more for drugs than other countries … again

NVIDIA and Google execs on the future of AI and drug discovery

hotspot

When prostate cancer spreads, where it goes matters

Telehealth for opioid use disorder is lifesaving

When prostate cancer spreads, where it goes matters

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

How to make the FDA’s new prescription one

Telehealth for opioid use disorder is lifesaving

focus

knowledge

leisure time

explore